Cargando…
Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study
In this small pilot sub-study, longitudinal gut microbiota composition changes, after successful treatment of hepatitis C virus (HCV) with the co-formulated glecaprevir/pibrentasvir (GLE/PIB), were analyzed before treatment (baseline) and 12 weeks post-treatment. Participating patients provided a fr...
Autores principales: | Yilmaz, Bahtiyar, Ruckstuhl, Lisa, Müllhaupt, Beat, Magenta, Lorenzo, Kuster, Melanie Harrer, Clerc, Olivier, Torgler, Ralph, Semmo, Nasser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472424/ https://www.ncbi.nlm.nih.gov/pubmed/34577631 http://dx.doi.org/10.3390/ph14090931 |
Ejemplares similares
-
A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study
por: Semmo, Nasser, et al.
Publicado: (2020) -
Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir
por: Aghemo, Alessio, et al.
Publicado: (2021) -
Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir
por: Aghemo, Alessio, et al.
Publicado: (2021) -
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
por: Cotter, Thomas G, et al.
Publicado: (2019) -
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
por: Reau, Nancy, et al.
Publicado: (2018)